In a mouse model, a drug conjugated with anti CD276 antibody, eradicated both large established tumours and metastases and improved long-term overall survival likely because of the targeting of both angiogenic and non-angiogenic intra-tumour blood vessels[44]. This evidence concerns the gene CD276 and neoplasm.